[NY-ESO-1和LAGE-1癌胚抗原在肝细胞癌中的表达]

[Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma].

作者信息

Zhang Wen-min, Xiao Gang, Zhang Meng, Guo Ai-lin, Dong Yu, Wen Jian-ming

机构信息

Department of Pathology, Zhongshan Medical College, Sun Yat-sen University, Guangzhou 510080, China.

出版信息

Zhonghua Bing Li Xue Za Zhi. 2005 Apr;34(4):202-5.

PMID:16091172

Abstract

OBJECTIVE

To study the role of NY-ESO-1 and LAGE-1 cancer-testis antigens as targets for immunotherapy and the relationship between corresponding gene expression and biologic behavior of hepatocellular carcinoma (HCC).

METHODS

The expression of NY-ESO-1 and LAGE-1 was studied in frozen tumor tissues from 30 cases of HCC by reverse transcriptase-polymerase chain reaction and immunohistochemistry. NY-ESO-1 expression and its distribution were further studied by immunohistochemistry in a tissue array contained 191 cases of HCC.

RESULTS

NY-ESO-1 and LAGE-1 mRNAs were expressed in 33.3% (10/30) and 16.7% (5/30) of HCC respectively. Either NY-ESO-1 or LAGE-1 was expressed in 36.7% (11/30) cases. NY-ESO-1 was expressed mainly in the cytoplasm of tumor cells. It was positive in 13.8% (24/174) cases of HCC. There was an increased expression of NY-ESO-1 from 6.8%, 3/44 in small HCC, 16.2%, 21/130 in advanced HCC and 23.1%, 12/52 in metastatic HCC. The expression in the non-metastatic group was 9.8% (12/122). The differences between the metastatic group and non-metastatic group (< 0.05) and between normal liver tissue and HCC (< 0.01) were statistically significant. There was no relationship between NY-ESO-1 expression and tumor size. NY-ESO-1 and LAGE-1 were not detected in adjacent normal liver tissue.

CONCLUSIONS

NY-ESO-1 and LAGE-1 are expressed in a high percentage of HCC, especially in cases with metastasis. It is thus possible that NY-ESO-1/LAGE-1 can serve as targets for antigen-specific immunotherapy in HCC and NY-ESO-1 peptide vaccination may be of use for patients with advanced HCC.

摘要

目的

研究NY - ESO - 1和LAGE - 1癌胚抗原作为免疫治疗靶点的作用，以及相应基因表达与肝细胞癌（HCC）生物学行为之间的关系。

方法

采用逆转录 - 聚合酶链反应和免疫组织化学方法，研究30例HCC冷冻肿瘤组织中NY - ESO - 1和LAGE - 1的表达。通过免疫组织化学在包含191例HCC的组织芯片中进一步研究NY - ESO - 1的表达及其分布。

结果

NY - ESO - 1和LAGE - 1 mRNA分别在33.3%（10/30）和16.7%（5/30）的HCC中表达。36.7%（11/30）的病例中NY - ESO - 1或LAGE - 1有表达。NY - ESO - 1主要在肿瘤细胞的细胞质中表达。在13.8%（24/174）的HCC病例中呈阳性。小肝癌中NY - ESO - 1的表达从6.8%（3/44）增加到进展期肝癌的16.2%（21/130）和转移性肝癌的23.1%（12/52）。非转移组的表达为9.8%（12/122）。转移组与非转移组之间（<0.05）以及正常肝组织与HCC之间（<0.01）的差异具有统计学意义。NY - ESO - 1表达与肿瘤大小无关。在相邻正常肝组织中未检测到NY - ESO - 1和LAGE - 1。